Find clinical trials for Lung Cancer in Hanyang, Seoul
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Lung Cancer trials near Hanyang, Seoul, KOR:
to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung...
Phase 2
Seoul, South Korea and 96 other locations
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...
Phase 2
Seoul, South Korea and 84 other locations
to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...
Phase 3
Seongnam-si, Gyeonggi-do, South Korea and 52 other locations
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
Seoul, Gangnam-gu, Korea, Republic of and 63 other locations
Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer....
Phase 1
Seoul, Korea, Republic of and 15 other locations
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...
Phase 2
Seoul, South Korea and 50 other locations
over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-sma ...
Phase 1
Seoul, Korea, Republic of and 38 other locations
Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung...
Phase 1
Seoul, Seoul Teugbyeolsi, South Korea and 27 other locations
type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...
Phase 1, Phase 2
Seoul, Korea, Republic of and 123 other locations
locally advanced or metastatic disease.In addition, HER3-DXd will be evaluated in participants with locally advanced or metastatic NSCLC whose tumors...
Phase 1
Seoul, South Korea and 36 other locations
Clinical trials
Research sites
Resources
Legal